Malek-Ahmadi, Michael
Su, Yi
Ghisays, Valentina
Luo, Ji
Devadas, Vivek
Chen, Yinghua
Lee, Wendy
Protas, Hillary
Chen, Kewei
Zetterberg, Henrik
Blennow, Kaj
Caselli, Richard J.
Reiman, Eric M.
Funding for this research was provided by:
National Institute on Aging (R01 AG031581, R01 AG069453, R37 AG011378, R01 AG041851, U01 AG006786, P30 AG072980, P30 AG019610, and P50 AG016574, R01 AG031581, R01 AG069453, R37 AG011378, R01 AG041851, U01 AG006786, P30 AG072980, P30 AG019610, and P50 AG016574, R01 AG031581, R01 AG069453, R37 AG011378, R01 AG041851, U01 AG006786, P30 AG072980, P30 AG019610, and P50 AG016574, R01 AG031581, R01 AG069453, R37 AG011378, R01 AG041851, U01 AG006786, P30 AG072980, P30 AG019610, and P50 AG016574, R01 AG031581, R01 AG069453, R37 AG011378, R01 AG041851, U01 AG006786, P30 AG072980, P30 AG019610, and P50 AG016574, R01 AG031581, R01 AG069453, R37 AG011378, R01 AG041851, U01 AG006786, P30 AG072980, P30 AG019610, and P50 AG016574, R01 AG031581, R01 AG069453, R37 AG011378, R01 AG041851, U01 AG006786, P30 AG072980, P30 AG019610, and P50 AG016574, R01 AG031581, R01 AG069453, R37 AG011378, R01 AG041851, U01 AG006786, P30 AG072980, P30 AG019610, and P50 AG016574, R01 AG031581, R01 AG069453, R37 AG011378, R01 AG041851, U01 AG006786, P30 AG072980, P30 AG019610, and P50 AG016574, R01 AG031581, R01 AG069453, R37 AG011378, R01 AG041851, U01 AG006786, P30 AG072980, P30 AG019610, and P50 AG016574, R01 AG031581, R01 AG069453, R37 AG011378, R01 AG041851, U01 AG006786, P30 AG072980, P30 AG019610, and P50 AG016574)
Arizona Department of Health Services (CTR040636, ADHS16‐121321, CTR040636, ADHS16‐121321, CTR040636, ADHS16‐121321, CTR040636, ADHS16‐121321, CTR040636, ADHS16‐121321, CTR040636, ADHS16‐121321, CTR040636, ADHS16‐121321, CTR040636, ADHS16‐121321, CTR040636, ADHS16‐121321, CTR040636, ADHS16‐121321)
Banner Alzheimer's Foundation
Arizona Alzheimer's Consortium
Swedish Research Council (2018-02532, 2017-00915)
European Research Council (681712)
Swedish State Support for Clinical Research (ALFGBG-720931)
Alzheimer's Drug Discovery Foundation (201809-2016862)
Alzheimer's Association (ADSF-21-831376-C, ADSF-21-831381-C, and ADSF-21-831377-C, ZEN-21-848495)
Olav Thon Foundation
Erling-Persson Family Foundation
Stiftelsen för Gamla Tjänarinnor
Hjärnfonden, Sweden (FO2019-0228, FO2017-0243)
H2020 Marie Skłodowska-Curie Actions (860197)
European Union Joint Program for Neurodegenerative Disorders (JPND2021-00694)
UK Dementia Research Institute
Swedish Alzheimer Foundation (AF-742881)
Swedish state under the agreement between the Swedish government and the County Councils
ALF-Agreement (ALFGBG-715986)
Article History
Received: 26 August 2022
Accepted: 28 March 2023
First Online: 10 April 2023
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki. All participants gave written informed consent to participate in the study. Ethical approval was given by the Western Institutional Review Board.
: Not applicable.
: HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. ERM is a scientific advisor to Alkahest, Alzheon, Aural Analytics, Denali, Green Valley, MagQ, Takeda, and United Neuroscience; he is also an advisor to Roche/Roche Diagnostics (expenses only); he is a principal investigator of prevention trials that include research agreements with Genentech/Roche and Novartis/Amgen, PET studies that include research agreements with Avid/Lilly, and several NIH and foundation-supported research studies; he is the inventor of a patent owned by Banner Health involving the use of biomarkers to accelerate the evaluation of Alzheimer’s disease prevention therapies; he is cofounder and shareholder of AlzPath, a new company, which aims to further develop blood-based biomarkers for AD and related diseases and advance their use in research, drug development, and clinical set tings.